natgillin/translations-raw huggingface dataset:
The Manufacturer's Instructions for Use will give full details on cleaning and disinfecting. 
V navodilih izdelovalca za uporabo najdete vse podrobnosti o čiščenju in razkuževanju.
Inner box 
Notranja škatla
- Difficulty in breathing which can range from mild to severe (bronchospasm). 
- Težave z dihanjem, ki so lahko blage do hude (bronhospazem).
However if it is nearly the time for your next dose, skip the missed dose. 
Če je že skoraj čas za naslednji odmerek, preskočite odmerek, ki ste ga pozabili uporabiti.
The affected limb(s) should be appropriately treated (e.g. immobilisation). 
Prizadeto okončino ali okončine je treba ustrezno obravnavati (npr. imobilizacija).
Transient vision loss 
prehodna izguba vida
Quinsair must not be used whilst pregnant or breast-feeding. 
Zdravila Quinsair se ne sme uporabljati med nosečnostjo ali dojenjem.
IV = intravenous; QD = quaque die (once a day); BID = bis in die (twice a day) * Predicted value from population PK analysis in CF patients ** Healthy males 18-53 years old 
= intravensko; QD = quaque die (enkrat na dan); BID = bis in die (dvakrat na dan) * Napovedana vrednost iz FK populacijske analize pri bolnikih s CF ** Zdravi moški, stari 18-53 let
Get urgent medical treatment immediately if you notice a severe allergic reaction after inhaling Quinsair. 
Takoj poiščite nujno zdravljenje, če po inhaliranju zdravila Quinsair opazite hudo alergijsko reakcijo.
Haemodialysis, including peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD), are not effective in removing levofloxacin from the body. 
Hemodializa, vključno s peritonealno dializo in kontinuirano ambulantno peritonealno dializo (CAPD), ni učinkovita pri odstranjevanju levofloksacina iz telesa.
In the “crimped area” on either side of the ampoule tail LOT 
"Stisnjen del" na obeh straneh spodnjega dela ampule Lot
Furthermore, clinical data do not suggest interaction with P-glycoprotein (P-gp) substrates such as digoxin. 
Klinični podatki nadalje ne kažejo na medsebojno delovanje s substrati P-glikoproteina (P-gp), kot je digoksin.
There is insufficient information on the excretion of levofloxacin in human milk; however, other fluoroquinolones are excreted in breast milk. 
Ni dovolj podatkov o izločanju levofloksacina v materino mleko, vendar se drugi fluorokinoloni izločajo v materino mleko.
Caution is recommended if levofloxacin is used in psychotic patients or in patients with a history of psychiatric disease. 
Previdnost se priporoča ob uporabi levofloksacina pri psihotičnih bolnikih ali pri bolnikih s psihiatrično boleznijo v anamnezi.
You may rarely experience symptoms of nerve damage (neuropathy) such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. 
Redko se lahko pojavijo simptomi poškodbe živcev (nevropatija), kot so bolečina, skelenje, mravljinčenje, odrevenelost in/ali šibkost, zlasti v stopalih in nogah ali dlaneh in rokah.
Treatment of these patients with levofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3). 
Zdravljenje teh bolnikov z levofloksacinom se sme uvesti le v primeru, da ni drugih možnosti zdravljenja, in po skrbni oceni razmerja med koristmi in tveganji (glejte tudi poglavje 4.3).
Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). 
Driska, zlasti huda, dolgotrajna in/ali krvava, med zdravljenjem z levofloksacinom ali po njem (vključno z več tedni po zdravljenju) je lahko znak bolezni, povezane s Clostridium difficile.
If aerosol mist does not begin to flow, please refer to the Zirela Manufacturer's Instructions for Use for help. 
Če aerosol ne začne pršeti, glejte navodila izdelovalca za sistem Zirela za pomoč.
If you forget to use Quinsair 
Če ste pozabili uporabiti zdravilo Quinsair
Cross-resistance between levofloxacin and other fluoroquinolones is observed. 
Opazili so navzkrižno odpornost med levofloksacinom in drugimi fluorokinoloni.
Weight decrease was reported as an adverse event during clinical studies, but was primarily thought to be disease rather than drug-related. 
Med kliničnimi študijami so kot o neželenem učinku poročali o zmanjšanju telesne mase, vendar prevladuje mnenje, da je to povezano z boleznijo in ne zdravilom.
You should avoid prolonged exposure to sunlight or strong sunlight and should not use sunbeds or any other UV lamps whilst using Quinsair and for 48 hours after stopping treatment. 
Preprečite dolgotrajno izpostavljanje sončni svetlobi ali močni sončni svetlobi in ne uporabljajte solarijev ali drugih UV-svetilk, medtem ko se zdravite z zdravilom Quinsair in še 48 ur po prenehanju zdravljenja.
Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. 
Študije na miših so pokazale, da levofloksacin deluje fototoksično le pri zelo velikih odmerkih.
Taking these medicines with Quinsair may lead to an increase in bleeding. 
Jemanje teh zdravil z zdravilom Quinsair lahko poveča krvavitve.
In vitro studies demonstrated that inhibition of the key transporters associated with drug disposition in the kidney (organic anion-transporting polypeptide-1B1 (OATP1B1), OATP1B3, organic anion transporter-1 (OAT1), OAT3 and organic cationic transporter-2 (OCT2)) at exposures following inhalation of 240 mg levofloxacin twice daily is low. 
Interakcije, pri katerih posredujejo učinki na prenašalce Študije in vitro so pokazale, da je zaviranje ključnih prenašalcev, povezanih z dispozicijo zdravila v ledvicah (transportnega polipeptida organskih anionov 1B1 (OATP1B1), OATP1B3, organskega anionskega prenašalca 1 (OAT1), OAT3 in organskega kationskega prenašalca 2 (OCT2)), ob izpostavljenosti po inhaliranju 240 mg levofloksacina dvakrat na dan nizko.
Tell your doctor if you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete nosečnost, se posvetujte z zdravnikom.
240 mg Inhalation BID 
240 mg inhalacija BID
Administration of Quinsair in patients with clinically significant haemoptysis should be undertaken only if the benefits of treatment are considered to outweigh the risks of inducing further haemorrhage. 
Zdravilo Quinsair naj se bolnikom s klinično pomembno hemoptizo daje le, če se oceni, da koristi zdravljenja presegajo tveganja za povzročitev nadaljnje krvavitve.
- Medicines such as probenecid (used to prevent gout) or cimetidine (used to treat ulcers). 
- Zdravila, kot je probenecid (uporablja se za preprečevanje protina) ali cimetidin (uporablja se za zdravljenje razjed).
In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential. 
Testi in vivo (mikronukleusni test, test izmenjave sestrskih kromatid, test nepredvidene sinteze DNA, dominantni letalni test) niso pokazali genotoksičnega potenciala.
How long do I use it for? 
Kako dolgo naj zdravilo uporabljam?
if you have been diagnosed with an enlargement or "bulge" of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm). 
če so vam postavili diagnozo povečanja ali „izbokline“ velike krvne žile (aortna anevrizma ali periferna anevrizma velike žile);
Carefully read the Manufacturer's Instructions for Use, provided with your Zirela Nebuliser Handset. 
Natančno preberite proizvajalčeva navodila za uporabo, priložena nebulatorju Zirela.
The recommended dosage is 240 mg (one ampoule) administered by inhalation twice daily (see section 5.2). 
Priporočeni odmerek je 240 mg (ena ampula), uporabljen v obliki inhalacije dvakrat na dan (glejte poglavje 5.2).
Quinsair can cause changes to your heart rhythm, especially if you are taking any medicines to treat heart problems or low levels of potassium or magnesium in the blood. 
Zdravilo Quinsair lahko povzroči spremembe srčnega ritma, zlasti ob jemanju zdravil za zdravljenje težav s srcem ali če imate v krvi nizke ravni kalija ali magnezija.
The development of fluoroquinolone-resistant P. aeruginosa and superinfection with fluoroquinolone-insusceptible microorganisms represent potential risks associated with the use of Quinsair. 
Razvoj na fluorokinolone odpornih bakterij P. aeruginosa in superinfekcija z mikroorganizmi, neobčutljivimi na fluorokinolone, predstavljata možna tveganja, povezana z uporabo zdravila Quinsair.
It is important that you keep using the medicine twice a day during your 28 days on treatment and that you keep to the 28-days on, 28-days off cycle for as long as your doctor tells you to. 
Pomembno je, da zdravilo v 28 dneh trajanja zdravljenja uporabljate dvakrat na dan in da upoštevate cikel 28-dnevnega jemanja, ki mu sledi 28-dnevna prekinitev, in sicer toliko časa, kot vam naroči zdravnik.
The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial DNA gyrase and topoisomerase IV enzymes. 
Mehanizem delovanja levofloksacina in drugih fluorokinolonskih protimikrobnih zdravil vključuje zaviranje bakterijske DNA giraze in encimov topoizomeraze IV.
The half-life of levofloxacin following inhalation of Quinsair is approximately 5 to 7 hours. 
Razpolovni čas levofloksacina po inhaliranju zdravila Quinsair je približno 5 do 7 ur.
These medicines may interfere with the effects of Quinsair. 
Ta zdravila lahko vplivajo na učinke zdravila Quinsair.
In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2) indicating that levofloxacin is not a CYP1A2 inhibitor. 
V študiji farmakokinetičnega medsebojnega delovanja levofloksacin ni vplival na farmakokinetiko teofilina (raziskovalni substrat za CYP1A2), kar kaže na to, da levofloksacin ni zaviralec CYP1A2.
Higher sputum concentrations were observed in adults compared to paediatric patients in Study 207; similar sputum concentrations were observed in adult and paediatric patients in Study 209. 
Pri odraslih so v primerjavi s pediatričnimi bolniki v študiji 207 opazili višje koncentracije v sputumu; pri odraslih in pediatričnih bolnikih so v študiji 209 opazili podobne koncentracije v sputumu.
Hearing loss* 
izguba sluha*
Press down and turn the cap clockwise as far as it will go (b, Figure 2). 
Pokrov za zdravilo pritisnite navzdol in ga obračajte v smeri urnega kazalca, dokler gre (b, slika 2).
- Coughing up blood or blood-stained mucus from the airways. 
- Izkašljevanje krvi ali krvave sluzi iz dihalnih poti.
Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone. 
Koncentracije levofloksacina so bile v prisotnosti fenbufena približno 13% večje kot tedaj, ko je bil levofloksacin uporabljen sam.
Hepatic impairment No dose adjustment is required (see section 5.2). 
Jetrna okvara Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
Efficacy was not evaluated in the 14 children with CF (≥ 6 to < 12 years old) and 13 adolescents with CF (≥ 12 to < 17 years old) who participated in Study 206. 
Učinkovitosti niso ovrednotili pri 14 otrocih s CF (≥ 6 do < 12 let) in 13 mladostnikih s CF (≥ 12 do < 17 let), ki so sodelovali v študiji 206.
It reduced tumour development in a photocarcinogenicity study. 
V študiji fotokarcinogenosti je zmanjšal razvoj tumorjev.
Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment. 
Tendinitis in pretrganje tetive (zlasti, a ne izključno, Ahilove tetive), včasih obojestransko, se lahko pojavita že v roku 48 ur od začetka zdravljenja s kinoloni in fluorokinoloni, o njiju pa so poročali tudi še več mesecev po prekinitvi zdravljenja.
a Treatment difference for Quinsair minus TIS, or Hazard ratio for Quinsair/TIS. 
a Razlika v zdravljenju za zdravilo Quinsair minus TIS ali razmerje tveganja za zdravilo Quinsair/TIS.
Ensure that you completely empty the ampoule, gently tapping it against the side of the reservoir if necessary. 
Ampulo do konca izpraznite tako, da z njo po potrebi nežno potolčete ob strani vsebnika.
If this becomes severe or persistent, or you notice blood in your stools, you should stop using Quinsair immediately and talk to your doctor. 
Če postane resna ali trdovratna ali če v blatu opazite kri, takoj prenehajte uporabljati zdravilo Quinsair in se posvetujte z zdravnikom.
Quinsair is supplied as a 28-day pack. 
Zdravilo Quinsair je na voljo kot 28-dnevno pakiranje.
Bronchospasm**, Bronchial hyper-reactivity, Obstructive airways disorder 
disfonija bronhospazem**, hiperreaktivnost bronhijev, obstruktivna motnja dihalnih poti
Clinical efficacy was demonstrated in two placebo-controlled studies and one active-comparator study in 448 patients randomised to receive Quinsair 240 mg twice daily. 
Klinična učinkovitost je bila dokazana v dveh s placebom nadzorovanih študijah in eni študiji z aktivnim primerjanim zdravilom s 448 bolniki, randomiziranimi za prejemanje zdravila Quinsair 240 mg dvakrat na dan.
Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations. 
Zato je pri teh populacijah potrebna previdnost pri uporabi fluorokinolonov, vključno z levofloksacinom.
The safety and efficacy of Quinsair in elderly patients with CF have not been established. 
Varnost in učinkovitost zdravila Quinsair pri starejših bolnikih s CF nista bili dokazani.
In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8). 
Pri sladkornih bolnikih se priporoča skrbno spremljanje glukoze v krvi (glejte poglavje 4.8).
Patients under treatment with levofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8). 
Bolnikom, ki se zdravijo z levofloksacinom, je treba svetovati, da morajo pred nadaljevanjem zdravljenja obvestiti zdravnika, če se pojavijo simptomi nevropatije, kot so bolečina, skelenje, mravljinčenje, odrevenelost ali šibkost, da se prepreči razvoj potencialno ireverzibilnega stanja (glejte poglavje 4.8).
If you are treated with Quinsair, you may have a severe skin reaction such as blistering or lesions. 
Če se zdravite z zdravilom Quinsair, boste morda imeli hude kožne reakcije, kot so mehurji ali lezije.
* Note: One adolescent randomised to Quinsair 240 mg twice daily did not receive study drug. 
* Opomba: En mladostnik, randomiziran za zdravilo Quinsair 240 mg dvakrat na dan, študijskega zdravila ni prejel.
What you need to know before you use Quinsair 
Kaj morate vedeti, preden boste uporabili zdravilo Quinsair
Patients who completed Study 209 (Core Phase) could continue in an optional Extension Phase for 3 additional cycles (i.e. 28 days of treatment with Quinsair 240 mg twice daily followed by 28 days off treatment). 
Bolniki, ki so zaključili študijo 209 (osrednjo fazo), so lahko nadaljevali v neobvezni fazi podaljška še 3 dodatne cikle (tj. 28 dni zdravljenja z zdravilom Quinsair 240 mg dvakrat na dan, ki mu je sledilo 28 dni brez zdravljenja).
Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. including angioedema and anaphylactic shock). 
Levofloksacin lahko povzroči resne, tudi smrtno nevarne preobčutljivostne reakcije (vključno z angioedemom in anafilaktičnim šokom).
Two randomised, double-blind, single-cycle, placebo-controlled clinical trials (Studies 204 and 207) in patients with CF chronically infected with P. aeruginosa were conducted. 
Izvedeni sta bili dve randomizirani, dvojno slepi s placebom nadzorovani klinični preskušanji z enim ciklom (študiji 204 in 207) pri bolnikih s CF in kronično okužbo s P. aeruginosa.
• Uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia). 
• nekorigiranem neravnovesju elektrolitov (npr. pri hipokaliemiji, hipomagneziemiji),
The safety and efficacy of Quinsair in children aged ˂ 18 years old have not yet been established (see section 4.2). 
Varnost in učinkovitost zdravila Quinsair pri otrocih, starih < 18 let, še nista bili dokazani (glejte poglavje 4.2).
At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with levofloxacin should be discontinued and alternative treatment should be considered. 
Ob prvem znaku tendinitisa (npr. boleča oteklina, vnetje) je treba zdravljenje z levofloksacinom prekiniti in razmisliti o drugem zdravljenju.
The safety of the recommended dose of Quinsair was evaluated in 472 patients with CF from two double-blind, single-cycle, placebo-controlled trials and from an active-comparator study with an optional uncontrolled extension. 
Varnost priporočenega odmerka zdravila Quinsair so ocenili pri 472 bolnikih s CF v dveh dvojno slepih, s placebom nadzorovanih preskušanjih in enim ciklom, ter v študiji z aktivnim primerjanim zdravilom z neobveznim nenadzorovanim podaljškom.
The mean apparent total body clearance of levofloxacin following systemic administration of a 500 mg single dose was 175 +/- 29.2 ml/min. 
Povprečni navidezni celokupni telesni očistek levofloksacina po sistemski uporabi enega odmerka 500 mg je bil 175 +/- 29,2 ml/min.
Four ampoules are sealed in a foil sachet and each box contains 14 sachets. 
Štiri ampule so nepredušno zaprte v vrečici iz folije; vsaka škatla vsebuje 14 vrečic.
If you forget a dose, use it as soon as you remember as long as there is an 8-hour interval before inhaling the next dose. 
Če pozabite na odmerek, ga uporabite takoj, ko se spomnite, če je do inhaliranja naslednjega odmerka še vsaj 8 ur.
Population pharmacokinetic analysis results showed no differences in systemic exposure of levofloxacin due to gender following administration of Quinsair. 
Populacijska farmakokinetična analiza ni pokazala razlik v sistemski izpostavljenosti levofloksacinu zaradi spola po uporabi zdravila Quinsair.
Some adverse reactions (e.g. fatigue, asthenia, visual disturbances, dizziness) may impair patient's ability to concentrate and react. 
Nekateri neželeni učinki (npr. utrujenost, astenija, motnje vida, omotica) lahko vplivajo na bolnikovo sposobnost koncentracije in reagiranja.
• Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia). 
• boleznih srca (npr. srčnem popuščanju, miokardnem infarktu, bradikardiji).
The European Medicines Agency has deferred the obligation to submit the results of studies with Quinsair in one or more subsets of the paediatric population in cystic fibrosis patients with P. aeruginosa pulmonary infection/colonisation (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Quinsair za eno ali več podskupin pediatrične populacije pri bolnikih s cistično fibrozo z okužbo/kolonizacijo z bakterijo P. aeruginosa (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• Epilepsy. 
• epilepsija
Inflammation and ruptures of tendons may occur within the first 48 hours of treatment and even up to several months after stopping of Quinsair therapy. 
Vnetje in pretrganja tetiv se lahko pojavijo že prvih 48 urah zdravljenja, lahko pa tudi več mesecev po uporabi zdravila Quinsair.
- Theophylline (used to treat breathing problems) or non-steroidal anti-inflammatory medicines (NSAIDs) such as fenbufen, acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting) or ibuprofen. 
- Teofilin (uporablja se pri težavah z dihanjem) ali nesteroidna protivnetna zdravila (NSAID), kot so fenbufen, acetilsalicilna kislina (snov, prisotna v številnih zdravilih, ki se uporabljajo za blaženje bolečine in nižanje telesne temperature, pa tudi za preprečevanje strjevanja krvi) ali ibuprofen.
Retching, Dyspepsia*, Flatulence* 
spahovanje, dispepsija*, flatulenca*
a ANCOVA with terms for treatment, region, age (16 to 18 years, > 18 years), and baseline FEV1 percent predicted as quartiles. 
a ANCOVA s pojmi zdravljenje, regija, starost (16 do 18 let, > 18 let), izhodiščni napovedani odstotek FEV1 v kvartilih.
If this happens, stop taking Quinsair and inform your doctor immediately in order to prevent the development of potentially irreversible condition. 
Če se to zgodi, prenehajte uporabljati zdravilo Quinsair in o tem takoj obvestite zdravnika, da preprečite razvoj potencialno ireverzibilnega stanja.
Keep the Zirela Instructions for Use in a safe place as they give full details on assembling the device. 
Navodila za uporabo sistema Zirela hranite na varnem, saj vsebujejo vse podrobnosti o sestavljanju pripomočka.
Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on foetuses was delayed maturation as a result of maternal toxicity. 
Levofloksacin ni imel škodljivega delovanja na plodnost ali sposobnost razmnoževanja pri podganah; edini učinek na zarodke je bilo zakasnjeno zorenje zaradi toksičnosti levofloksacina za mater.
During the Extension Phase, the LS Mean change for FEV1 percent predicted ranged between 4.83% to 1.46% across the 3 additional treatment cycles. 
V fazi podaljška je bila sprememba povprečne vrednosti LS za napovedani odstotek FEV1 od 4,83% do 1,46% v 3 dodatnih ciklih zdravljenja.
- Ciclosporin (used after organ transplants) or medicines that affect your heart beat (such as antiarrhythmics, tricyclic antidepressants, macrolide antibiotics or antipsychotics). 
- Ciklosporin (uporablja se po presaditvi organov) ali zdravila, ki vplivajo na srčni utrip (kot so antiaritmiki, triciklični antidepresivi, makrolidni antibiotiki ali antipsihotiki).
Patients should not inhale the contents of more than one ampoule to compensate for the missed dose. 
Bolnik ne sme inhalirati vsebine več kot ene ampule, da bi nadomestil izpuščeni odmerek.
2) Squeeze all of the contents of one ampoule into the medicine reservoir of the Zirela Nebuliser Handset (Figure 1). 
2) Vso vsebino ene ampule iztisnite v vsebnik za zdravilo nebulatorja Zirela (slika 1).
Tell your doctor before using Quinsair if you have or have ever had any of the following: - Prolonged, disabling and potentially irreversible serious side effects Fluoroquinolone/quinolone antibacterial medicines, including Quinsair, have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. 
Pred začetkom uporabe zdravila Quinsair povejte zdravniku, če imate ali ste kdaj imeli kaj od naslednjega: - Dolgotrajni, onesposabljajoči in potencialno ireverzibilni resni neželeni učinki Protibakterijska zdravila, ki vsebujejo fluorokinolone/kinolone, vključno z zdravilom Quinsair, so bila povezana z zelo redkimi, a zelo resnimi neželenimi učinki, od katerih so nekateri dolgotrajni (trajajo več mesecev ali let), onesposabljajoči ali potencialno ireverzibilni.
- Vision problems 
- Težave z vidom
Other medicines and Quinsair 
Druga zdravila in zdravilo Quinsair
Resistance to levofloxacin, other antibacterial agents and treatment-emergent microorganisms 
Odpornost na levofloksacin, druga protibakterijska zdravila in mikroorganizme, ki se pojavijo ob zdravljenju
Ventricular tachycardia, Ventricular arrhythmia and torsade de pointes 
Srčne bolezni palpitacije ventrikularna tahikardija, ventrikularna aritmija in torsade de pointes
In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. 
Podobno kot drugi fluorokinoloni je tudi levofloksacin vplival na hrustanec (pojav mehurjev in votlin) pri podganah in psih.
TIS 300 mg BID N = 93 
TIS 300 mg dvakrat na dan N = 93